Shanghai-listed biopharmaceutical firm Haohai Biotech reported to the Hong Kong Stock Exchange that it repurchased 62,500 H shares on 27 October 2026, paying between HK$15.78 and HK$16.10 per share for a total consideration of HK$0.99 million. The shares, acquired on-market, are earmarked for cancellation and have not yet been retired.

Including this latest transaction, Haohai Biotech has bought back 1,023,800 H shares since its 29 May 2026 shareholder mandate, equal to 2.94 % of the company’s issued share capital (excluding treasury shares) on the mandate date. The cumulative outlay for these repurchases amounts to roughly HK$16.34 million, utilising about 29 % of the 3.48 million H shares authorised for buyback.

As of 27 October 2026, Haohai Biotech’s issued share capital comprises 190.20 million A shares listed on Shanghai’s STAR Market and 34.78 million H shares listed in Hong Kong, totaling 224.98 million ordinary shares. The company also holds 3.85 million A shares in treasury. The latest buyback keeps the number of issued H shares unchanged at 34.78 million until cancellation is completed.

Under Hong Kong listing rules, Haohai Biotech is restricted from issuing new shares or selling treasury shares for 30 days following the 27 October repurchase, setting a moratorium period that runs through 26 November 2026.